Making clinical trials accessible to everyone.

Active Studies

Below are active studies being conducted by Macro Trials. We are constantly opening new studies in many other therapeutic areas, so please join our registry and check back regularly.

Asthma

GSK 206785 -  NIMBLE
Now Enrolling

A phase 3, 52-week, randomized, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab

Investigator: 
C. Andrew Schroeder, MD

Chronic Obstructive Pulmonary Disease (COPD)

EFC16750 - AERIFY-1
Now Enrolling

Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340 / REGN3500 / Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Investigator: 
C. Andrew Schroeder, MD

Diabetic Macular Edema

D-4517.2 - Tejas
Now Enrolling

A Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)

Investigator: 
David Lazar, MD

Macular Degeneration (Prior IVT Treatment)

D-4517.2 - Tejas
Now Enrolling

A Phase 2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)

Investigator: 
David Lazar, MD

Macular Degeneration (Treatment-Naive)

HLX04-O-wAMD
Now Enrolling

A Phase 3, Randomized, Double-masked, Active Controlled Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection With Ranibizumab in Subjects With Wet Age-related Macular Degeneration (wAMD)

Investigator: 
David Lazar, MD

Thyroid Eye Disease

IMVT-1401-3201
Now Enrolling

A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)

Investigator: 
David Lazar, MD